AKAkshy Kumar

Akshy Kumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Akshy Kumar has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating mortality burden of diabetes mellitus and peripheral arterial disease in the United States: insights from 26 years of national data

    by Ghazi Uddin Ahmed, Usha Kumari, Yogita Kumari, Soni Rani, Beesham Kumar Lohana, Akshy Kumar, Aniket Tara, Sahil Raj, Payal Kumari, Nikeeta Bai, et al.

    Background: Diabetes mellitus (DM) and peripheral arterial disease (PAD) are major contributors to mortality across the United States. Monitoring long-term mortality trends and demographic disparities is essential for guiding public health strategies aimed at high-risk populations. Methods: This retrospective analysis utilized mortality data from the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database, covering the years 1999 through 2024. Deaths in which DM (ICD-10: E10–E14, O24, P70.2) and PAD (ICD-10: I70–I78) were documented as either primary or contributing causes were included. Age-adjusted mortality rates (AAMRs) per 100 000 people were calculated and stratified by year, gender, race/ethnicity, state, and urban-rural classification. Joinpoint regression analysis was used to identify significant changes in AAMR trends, quantified as annual percent changes. Results: A total of 274 117 deaths among individuals aged 15 and older were linked to both DM and PAD. Nationally, AAMR decreased from 4.3 in 1999 to 2.2 in 2024. Men consistently had higher AAMRs (3.9) than women (2.5). Among racial/ethnic groups, non-Hispanic American Indian or Alaska Native populations had the highest mortality rate (5.2). States such as West Virginia, Oklahoma, California, Vermont, and Ohio had the greatest AAMRs. Rural (nonmetropolitan) areas had higher rates (3.6) than metropolitan regions (3.0). Conclusions: Despite overall reductions in mortality, disparities by sex, race/ethnicity, and geography persist. The objective of this study was to explicitly assess long-term mortality trends and demographic disparities associated with DM and PAD in the United States, providing evidence to guide future preventive and policy measures. These results underscore the importance of targeted and equity-driven health interventions to reduce the burden of DM and PAD nationwide.


  • Open Access

    Once-weekly insulin icodec vs. daily insulin glargine in type 2 diabetes: a meta-analysis with longitudinal insights

    by Taimoor Ashraf, Akshy Kumar, Aniket Tara, Naila Memon, Areej Muhammad, Muskan Turesh, Shah Dev, Noor Muhammad, Vikash Kumar, Tooba Hussain, et al.

    Introduction: Type 2 diabetes mellitus (T2DM) is a progressive condition often necessitating insulin therapy for sustained glycemic control, yet adherence to daily injections remains a significant challenge. While insulin glargine is effective, reducing injection frequency may improve compliance and outcomes. This study evaluates the efficacy and safety of once-weekly insulin icodec compared to once-daily insulin glargine U100. Methods: This systematic review and meta-analysis followed Cochrane and PRISMA guidelines. A comprehensive search across multiple databases identified randomized controlled trials (RCTs) comparing once-weekly insulin icodec with once-daily insulin glargine U100 in adults with T2DM. Eligible studies included adult participants and reported glycemic or safety outcomes. Data synthesis was performed using a random-effects model, with heterogeneity assessed via the I2 statistic. Results: Five RCTs comprising 2,019 participants met the inclusion criteria. Insulin icodec significantly reduced glycated hemoglobin (MD: −0.12; 95% CI: −0.20, −0.04; P = 0.003) and increased time in range (TIR; MD: 4.23; 95% CI: 2.20, 6.26; P < 0.0001) compared to insulin glargine. A modest increase in body weight was observed with insulin icodec, while safety profiles, including hypoglycemia rates and adverse events, were comparable between treatments. Conclusion: Insulin icodec provides a safe and effective alternative to once-daily insulin glargine for T2DM management, offering similar glycemic control with a once-weekly dosing regimen. The reduced injection burden may enhance adherence and treatment satisfaction, potentially improving long-term disease outcomes.